Second Dose of the BNT162b2 mRNA Vaccine in Greece: The Value of Timely Administration

8 Pages Posted: 1 Apr 2021

See all articles by Konstantina Kontopoulou

Konstantina Kontopoulou

G. Gennimatas General Hospital

Alexandra Ainatzoglou

Aristotle University of Thessaloniki - Department of Clinical Pharmacology

Christos Nakas

University of Bern - University Institute of Clinical Chemistry; University of Thessaly

Athina Ifantidou

G. Gennimatas General Hospital

Georgia Goudi

G. Gennimatas General Hospital

Eleni Antoniadou

G. Gennimatas General Hospital

Vasilios Adamopoulos

G. Gennimatas General Hospital

Nikitas Papadopoulos

G. Gennimatas General Hospital

Georgios Papazisis

Aristotle University of Thessaloniki - Department of Clinical Pharmacology

Date Written: March 8, 2021

Abstract

Aim: Our study aimed to assess the generation of neutralizing antibodies elicited 14 days post-injection of each dose of the BNT162b2 in 401 Greek healthcare workers, 59 of whom were previously-infected.

Methods: The SARS-CoV-2 IgG II Quant assay on the Architect System was employed to monitor titers of neutralizing IgG against the receptor-binding domain of the S1 subunit of the spike protein in participant-derived serum samples.

Results: After the first dose, titers were found to fluctuate with age, marking a significant decline in the 50-60 age group, while dropping even further in participants aged over 60. This difference was surmounted following the second dose, as the fold-changes recorded were significantly higher in the 50-60 age group, while escalating in subjects aged over 60. After the second dose, the respective fold-change reached significance only among the uninfected, while being marginal in the seropositive group. The immune response of previously-infected subjects to the first dose was more intense than the respective response of the uninfected to the second dose.

Conclusion: Our findings suggest the importance of the timely administration of the second dose in the wide age range of 20-67 of our study cohort, questioning however its value among the seropositive.

Note: Trial Registration: The trial is registered on the International Standard Randomized Controlled Trial Number registry (study ID: ISRCTN61884303).

Funding Statement: None.

Declaration of Interests: None to declare.

Ethics Approval Statement: The study protocol was reviewed and approved by the Scientific Committee of the “G. Gennimatas” General Hospital (protocol number:1/13.1.2021).

Keywords: BNT162b2 mRNA vaccine, immunogenicity, seropositive, Greece

Suggested Citation

Kontopoulou, Konstantina and Ainatzoglou, Alexandra and Nakas, Christos and Ifantidou, Athina and Goudi, Georgia and Antoniadou, Eleni and Adamopoulos, Vasilios and Papadopoulos, Nikitas and Papazisis, Georgios, Second Dose of the BNT162b2 mRNA Vaccine in Greece: The Value of Timely Administration (March 8, 2021). Available at SSRN: https://ssrn.com/abstract=3800040 or http://dx.doi.org/10.2139/ssrn.3800040

Konstantina Kontopoulou

G. Gennimatas General Hospital ( email )

Eth. Aminis 41
Thessaloniki, 54635
Greece

Alexandra Ainatzoglou

Aristotle University of Thessaloniki - Department of Clinical Pharmacology ( email )

Greece

Christos Nakas

University of Bern - University Institute of Clinical Chemistry ( email )

Bern
Switzerland

University of Thessaly ( email )

Gaiopolis Campus
Larissa, 41110
Greece

Athina Ifantidou

G. Gennimatas General Hospital

Eth. Aminis 41
Thessaloniki, 54635
Greece

Georgia Goudi

G. Gennimatas General Hospital

Eth. Aminis 41
Thessaloniki, 54635
Greece

Eleni Antoniadou

G. Gennimatas General Hospital ( email )

Eth. Aminis 41
Thessaloniki, 54635
Greece

Vasilios Adamopoulos

G. Gennimatas General Hospital

Eth. Aminis 41
Thessaloniki, 54635
Greece

Nikitas Papadopoulos

G. Gennimatas General Hospital

Eth. Aminis 41
Thessaloniki, 54635
Greece

Georgios Papazisis (Contact Author)

Aristotle University of Thessaloniki - Department of Clinical Pharmacology ( email )

Greece

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
158
Abstract Views
659
rank
221,838
PlumX Metrics